MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.

MLA

Aarnoudse, Albert L. H. J., et al. “MDR1 Gene Polymorphisms Are Associated with Neuropsychiatric Adverse Effects of Mefloquine.” Clinical Pharmacology & Therapeutics, vol. 80, no. 4, Oct. 2006, pp. 367–74. EBSCOhost, https://doi.org/10.1016/j.clpt.2006.07.003.

APA

Aarnoudse, A. L. H. J., van Schaik, R. H. N., Dieleman, J., Molokhia, M., van Riemsdijk, M. M., Ligthelm, R. J., Overbosch, D., van der Heiden, I. P., & Stricker, B. H. C. (2006). MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clinical Pharmacology & Therapeutics, 80(4), 367–374. https://doi.org/10.1016/j.clpt.2006.07.003

Chicago

Aarnoudse, Albert L. H. J., Ron H. N. van Schaik, Jeanne Dieleman, Mariam Molokhia, Melanie M. van Riemsdijk, Robert J. Ligthelm, David Overbosch, Ilse P. van der Heiden, and Bruno H. Ch. Stricker. 2006. “MDR1 Gene Polymorphisms Are Associated with Neuropsychiatric Adverse Effects of Mefloquine.” Clinical Pharmacology & Therapeutics 80 (4): 367–74. doi:10.1016/j.clpt.2006.07.003.